Acetyl octapeptide-3 (SNAP-8)
Also known as: SNAP-8, Acetyl octapeptide-3, Acetyl-glu-glu-met-gln-arg-arg-ala-asp-amide
Overview
Acetyl octapeptide-3—often marketed as SNAP-8—is a synthetic cosmetic peptide used in topical formulations aimed at reducing the appearance of expression lines. It is commonly described as an 'Argireline-like' peptide in marketing materials, but it is a distinct sequence and should be treated as a cosmetic ingredient rather than a therapeutic peptide. In the peptide marketplace, SNAP-8 sometimes gets grouped with injectable or systemic 'wellness' peptides, yet its mainstream use case is topical skincare. That matters for risk interpretation: topical cosmetic use does not imply systemic bioavailability, and systemic claims would require entirely different evidence. For reference purposes, the most reliable public identifiers come from chemical registries (CAS, PubChem), which list synonyms and composition details used by suppliers and formulators.
Mechanism of Action
Often described as a peptide intended to modulate neuromuscular signaling related to expression lines; independent clinical mechanism validation is limited and many claims are marketing-driven. Treat as a topical cosmetic ingredient unless evidence supports otherwise.
Potential Benefits
- Marketed as a topical ingredient for reducing the appearance of expression lines.
- Used in cosmetic formulations alongside other peptides such as Matrixyl and Argireline.
- Generally stable in topical aqueous formulations.
Research Dosage Notes
The following reflects doses used in published research studies. This is not medical advice.
Consult published research literature for study-specific protocols.
Routes of Administration
Topical Limited; cosmetic surface-level use.
Systemic absorption is not the expected route.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Reconstitution
| Storage | Per product label |
|---|
Need exact syringe measurements?
Amino Acid Sequence
Acetyl-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2
Side Effects & Safety
- Topical irritation possible in sensitive skin types.
- Allergic contact dermatitis reported rarely with peptide-containing serums.
- Systemic effects not characterized.
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Known peptide allergy
Patch test recommended for sensitive skin.
Drug Interactions
- Other topical cosmetic actives: Formulation-dependent; topical irritants combined with peptide serums may increase irritation potential.
Pharmacokinetics
| Half-Life | Not characterized for topical cosmetic ingredients in the same way as systemic peptide drugs. |
|---|---|
| Storage | Per cosmetic formulation supplier guidance. |
Synergistic Compounds
The following compounds have been studied alongside Acetyl octapeptide-3 (SNAP-8) for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.